Cytogenetic analyses in acute myeloid leukemia (AML) and acute lymphoblastic leukemia
(ALL) have revealed a great number of non-random chromosome abnormalities. In many …

This is a comprehensive overview on the most recent developments in diagnosis and
treatment of acute lymphoblastic leukemia (ALL). Dr. Dieter Hoelzer and colleagues give an …

Imatinib mesylate, an inhibitor of the Bcr-Abl tyrosine kinase, has modest activity in
refractory/relapsed Philadelphia chromosome (Ph)-positive acute lymphocytic leukemia …

Abstract The translocation (9; 22) gives rise to the p190Bcr-Abl and p210Bcr-Abl tyrosine
kinase proteins, considered sufficient for leukemic transformation. Philadelphia-positive …

The best strategy for incorporating imatinib in front-line treatment of Ph+ acute lymphoblastic
leukemia (ALL) has not been established. We enrolled 92 patients with newly diagnosed …

The BCR-ABL fusion, the molecular equivalent of the Philadelphia translocation, gains
importance for treatment stratification in adult acute lymphoblastic leukemia (ALL). In this …

This study aimed to determine the impact of tyrosine kinase inhibitors given pre-and post-
allogeneic stem cell transplantation on long-term outcome of patients allografted for …

The present invention relates to a genetically engineered, CD19-specific chimeric T cell
receptor and to immune cells expressing the chimeric receptor The present invention also …

Between 1988 and 1999, 127 patients with poor-risk acute lymphoblastic leukemia (ALL)
received a matched unrelated donor transplant using marrow procured by National Marrow …

In adult Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL),
minimal residual disease (MRD) after stem cell transplantation (SCT) is associated with a …